Karyopharm’s Selinexor Demonstrates High Response Rates in Heavily-treated Multiple Myeloma Patients
Updated results from a Phase 2b clinical trial continue…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreUpdated results from a Phase 2b clinical trial continue…
In an effort to inform multiple myeloma patients…
SELLAS Life Sciences’ lead therapy candidate galinpepimut-S (GPS)…
Leukogene Therapeutics, a startup company from the…
Backed by former Major League Baseball All-Stars Dave…
The European Commission has approved the anti-CD38 antibody Darzalex…